Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target.
Monaldi Arch Chest Dis
; 91(2)2021 May 04.
Article
in English
| MEDLINE | ID: covidwho-1215533
ABSTRACT
To the Editor COVID-19 (COrona VIrus Disease) patients with cardiovascular (CV) disease, multiple CV risk factors or comorbidities (i.e., arterial hypertension and diabetes) were shown to be more prone to a worse prognosis. SARS-CoV-2 is a still unknown enemy and the role of concomitant cardiovascular therapies has been controversial in the early stages, particularly with regard to Angiotensin-Converting Enzyme inhibitors...
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Heart Disease Risk Factors
/
COVID-19
/
Hyperlipidemias
/
Hypolipidemic Agents
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS